Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.65 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.65 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.65 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.66 |
| ▸ | CA5A | P35218 | 1/20 | 0.66 |
| ▸ | MMP2 | P08253 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | F2 | P00734 | 3/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | DDX3X | O00571 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33350 | 0.98 | KMT2A (0.72) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL6525363 | 0.98 | KMT2A (0.72) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL9471995 | 0.98 | KMT2A (0.72) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL33351 | 0.98 | KMT2A (0.72) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL1063227 | 0.96 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A | |
| Ammonia Solution, Strong SCHEMBL9479957 | 0.96 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL4579511 | 0.96 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A | |
| Hydrochloric Acid SCHEMBL8975909 | 0.96 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL10474225 | 0.96 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A | |
| SCHEMBL28942184 | 0.96 | KMT2A (0.70) | KMT2AGAAHTTCA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062773-B | Method for acid-catalyzed cyclization reaction of 4-hydroxycoumarin and isoprene | 中国科学院大连化学物理研究所 | 2021-11-26 | — | — | CN | claimed |
| EP-0619302-B1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AG (DE) | 1997-03-12 | — | — | EP | claimed |
| US-5451699-A | Process for the preparation of crystalline, salt-free, chlorine-substituted 3-nitrobenzenesulfonic acid hydrates | HOECHST AG (DE) | 1995-09-19 | — | — | US | claimed |
| EP-0619302-A1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-12 | — | — | EP | claimed |
| JP-7048339-A | — | — | None | — | — | JP | disclosed |
| CN-112654619-B | Tricyclic furan substituted piperidine diketone compound | 南京明德新药研发有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11319330-B2 | Tricyclic furan-substituted piperidinedione compound | MEDSHINE DISCOVERY INC. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210317138-A1 | TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| CN-107540670-B | Preparation method of 1- (3-chloropyrazolo [1,5a ] -4,5,6, 7-tetrahydropyridine-2-yl) -5-methylamine pyrazole-4-carbonitrile | 湖北相和精密化学有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3848371-A1 | TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-112654619-A | Tricyclic furan substituted piperidine diketone compound | 南京明德新药研发有限公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-0619302-B1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| EP-0619302-B1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| US-5451699-A | Process for the preparation of crystalline, salt-free, chlorine-substituted 3-nitrobenzenesulfonic acid hydrates | HOECHST AG (DE) | 1995-09-19 | — | — | US | disclosed |
| JP-H0748339-A | PREPARATION OF SALT-FREE, CHLORINE-SUBSTITUTED CRYSTALLINE 3-NITROBENZENESULFONIC ACID HYDRATE | HOECHST AG | 1995-02-21 | — | — | JP | disclosed |
| EP-0619302-A1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-12 | — | — | EP | disclosed |
| EP-0619302-A1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-12 | — | — | EP | disclosed |
| EP-0619302-A1 | Process for the preparation of crystallized, salt-free, chlorosubstituted 3-nitrobenzene sulfonic acid hydrates | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319330-B2 | Tricyclic furan-substituted piperidinedione compound | CRBN, PFDN1, CLNS1A | MMP1 4174/4885MMP8 3430/4885MMP13 4273/4885 |
| US-20210317138-A1 | TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND | CRBN, PFDN1, CLNS1A | MMP1 4174/4885MMP8 3430/4885MMP13 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.